Form 4 for OKUR OnKure Therapeutics, Inc.
Accepted 2021-07-15 00:00:00 ET · period of report 2021-07-14 · accession 0001209191-21-046802 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-15 | 2021-07-14 | OKUR | Johnson Wendy S. | Chief Development Off | S - Sale | $8.50 | -111.7K | 0 | -100% | -$949.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-14 | S | D | 111,736 | $8.50 | 0 | D | — | — | (F1) The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth. |